**Market Need**

Alzheimer's disease (AD) is the sixth leading cause of death in the United States and is on pace to cost the nation $1.1 trillion by 2050. The global market projections for AD are expected to reach $6.2 billion by 2020. Beyond AD, the global neurodegenerative disease (NDD) market is expected to reach $45 billion by 2022. M3 Biotechnology’s novel family of therapeutics has the potential to address AD and the broader NDD market as a whole.

**Introduction**

M3 Biotechnology (M3) is a clinical-stage therapeutics company with a platform of novel disease-modifying regenerative small molecules being developed with the potential to stop disease progression and even restore lost function. While developing a pipeline of assets, M3 has now advanced a lead candidate, for Alzheimer’s disease (AD), to first-in-human Phase I clinical trials assessing safety, toxicity and tolerability while also evaluating a novel biomarker for AD.

M3’s novel assets act on trophic factors of a highly conserved mechanism of action. The core technology and lead candidate has the potential to address neurodegenerative therapies broadly. The company has optimized a lead compound for a first indication in AD, launched clinical trials and expanded the therapeutics pipeline. Current drugs on the market for Alzheimer’s patients offer only symptomatic relief, whereas M3 anticipates the lead candidate will slow, halt and potentially restore lost function.

**Intellectual Property and Pipeline Portfolio**

M3 Biotechnology’s intellectual property estate protects all compositions of matter and utility in CNS and across broader therapeutic indications. A fresh set of patents, filed globally across major markets, further strengthens the company’s IP position. Additionally, several drug candidates have been identified addressing indications beyond AD and neurodegenerative diseases.

<table>
<thead>
<tr>
<th>DISCOVERY</th>
<th>LEAD IDENTIFICATION &amp; OPTIMIZATION</th>
<th>IND ENABLING</th>
<th>PHASE I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s Disease</td>
<td>NDX-1017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson’s Disease</td>
<td>PRK-102</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurodegenerative Disease (AD, ALS, MS)</td>
<td>NDX-2000 series</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Financial Support**

M3 Biotechnology has received financial support from groups focused on innovative companies developing technologies addressing huge unmet medical needs with an emphasis on Alzheimer’s disease.

**Team**

**Leadership**

- Leen Kawas, PhD – President & CEO
- John M. Fluke, Jr. – Chairman
- Glenna Milesen – CFO

**Board of Directors**

- John M. Fluke, Jr. – Chairman
- Bruce Montgomery, MD
- Michael J. Montgomery
- Joseph W. Harding, PhD
- Leen Kawas, PhD

**Advisory Boards**

- Lance Stewart, PhD, MBA – Chairman
- Larry Ereshefsky, PharmD, BCPP, FCCP
- Bruce Montgomery, MD
- David Weiner, MD

**Contact**

Leen Kawas, PhD
President and CEO
Office: 206-616-4548
Cell: 206-602-9246
Email: leen.kawas@m3bio.com

Marie Higinbotham
Executive Assistant
Office: 206-221-8112
Cell: 206-613-9841
Email: marie.higinbotham@m3bio.com